| Name | Title | Contact Details |
|---|
Ancillary Supply Chain, Simplified Ancillare is the leader in end-to-end global clinical trial ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations. Ancillare is the first organization of its kind with an exclusive focus on the global clinical trial ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics, and regulatory experts. Ancillare`s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain. Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.
Organic Cannabis Foundation is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aktiv Pharma Group is a company that develops drug delivery technology for emergency situations, with a focus on the ARAI auto injector for opioid overdose, hypoglycemia, and severe allergies like anaphylaxis.
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. With operations in more than 30 nations and over 12,000 employees worldwide, we develop and deliver biotherapies to prevent and treat people with life-threatening medical conditions. Our broad-range of therapies include those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want. For a century, CSL Behring has earned a reputation as a passionate yet responsible organization, driven to care for patients and deliver on its commitments.